Kinetics of recovery from opioids at wild-type and mutant μ opioid receptors expressed in Xenopus oocytes

Synapse

Volumn 38, Issue 3, 2000, Pages 254-260

  Spivak, Charles E ^a   Beglan, Carol L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

G protein coupled receptor; GIRK1; Steric model; Voltage clamp

Indexed keywords

COMPLEMENTARY DNA; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETORPHINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; METAZOCINE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; NORMORPHINE; OPIATE AGONIST; ORIPAVINE; PENTAZOCINE; POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; DRUG ABUSE; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MUTAGENESIS; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS;

EID: 0034567819     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(20001201)38:3<254::AID-SYN4>3.0.CO;2-9     Document Type: Article

References (40)

1. Long-term effects of amphiphile congeners of etorphine suggest interracial location of μ-opioid receptor recognition site
2. Mutagenesis of a single amino acid in the rat mu-opioid receptor discriminates ligand binding
3. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors
4. Molecular cloning and functional expression of a μ-opioid receptor from rat brain
5. Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction
6. + channels
7. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists
8. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and the effects of mutating receptors
9. Structure-function analysis of the β-adrenergic receptor
10. 3D modeling, ligand binding and activation studies of the cloned mouse δ, μ and κ opioid receptors
11. Primary structures and expression from cDNAs of rat opioid receptor δ- and μ-subtypes
12. Location of regions of the opioid receptor involved in selective agonist binding
13. Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist
14. Mutagenesis of the human 5-HT1B receptor: Differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction
15. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine
16. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors
17. Efficacy and kinetics of opioid action on acutely dissociated neurons
18. Quantitative stereo-structure-activity relationships 1. Opiate receptor binding
19. Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor
20. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor
21. Structure-activity correlations of morphine-like analgetics based on efficiencies following intravenous and intraventricular applications
22. Apparent thermodynamic parameters of ligand binding to the cloned rat μ-opioid receptor
23. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor
24. A steric theory of opioid agonists, antagonists, agonist-antagonists, and partial agonists
25. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the muopioid-receptor gene
26. Replacement of Gin(280) by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids
27. Drug addiction and drug abuse
28. Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis
29. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints
30. Opioid analgesics and antagonists
31. Naloxone activation of μ opioid receptors mutated at a histidine residue lining the opioid binding cavity
32. Comparative modeling and molecular dynamics studies of the δ, κ and μ opioid receptors
33. μ Opiate receptor: Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity
34. Cloning and pharmacological characterization of a rat μ opioid receptor
35. Opiate receptor: cDNA cloning and expression
36. Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding
37. Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine 1D receptor: Importance of the second extracellular loop and fifth transmembrane domain in antagonist binding
38. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor
39. A potent and selective endogenous agonist for the μ-opiate receptor
40. A method for determining the unitary functional capacity of cloned channels and transporters expressed in Xenopus laevis oocytes